Deucrictibant
Hereditary Angioedema With C1Inh Deficiency
Institute for Asthma and AllergySmall moleculePhase 3Active
BBB
78/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 69/ 100
- Competitive Position
- 95/ 100
Competitive context
0 Active assets in the Hereditary Angioedema With C1Inh Deficiency cohort.
| Asset / Sponsor | Phase | Rating |
|---|
Same molecule, other indications
Deucrictibant is also rated in:
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →